Orencia (Abatacept) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Orencia (abatacept) is a prescription medication used to treat certain autoimmune diseases. It is classified as a selective T-cell co-stimulation modulator, which works by suppressing overactive immune responses that cause inflammation and tissue damage.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The key formulations of orencia (abatacept) include prefilled syringes and vials. A prefilled syringe contains a single dose of the medication and is used to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis. These formulations are used for various applications, including rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis, and are distributed through different channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The orencia (abatacept) market research report is one of a series of new reports from The Business Research Company that provides orencia (abatacept) market statistics, including orencia (abatacept) industry global market size, regional shares, competitors with a orencia (abatacept) market share, detailed orencia (abatacept) market segments, market trends and opportunities, and any further data you may need to thrive in the orencia (abatacept) industry. This orencia (abatacept) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The orencia (abatacept) market size is expected to see rapid growth in the next few years. It will grow to $4,733.5 million in 2029 at a compound annual growth rate (CAGR) of 12%. The growth in the forecast period can be attributed to increasing adoption of personalized medicine, growing patient preference for less invasive subcutaneous administration, expansion in emerging markets with rising healthcare access, the ongoing shift toward biologic therapies due to their superior efficacy and safety profiles. Major trends in the forecast period include improving reimbursement scenarios in developed markets, a shift towards biosimilars and cost-effective alternatives, partnerships, product approvals.

The increasing prevalence of autoimmune disorders is expected to drive the growth of the orencia (abatacept) market in the future. Autoimmune disorders occur when the immune system mistakenly attacks the body's own cells, tissues, or organs, resulting in inflammation and damage. This leads to chronic conditions like rheumatoid arthritis and multiple sclerosis, which have causes rooted in both genetic and environmental factors. The rise in autoimmune disorders is attributed to factors such as genetic predisposition, environmental triggers, and greater awareness and diagnosis, leading to more cases being identified. Orencia (abatacept) aids in managing autoimmune diseases by modulating the immune response through selective T-cell costimulation inhibition, thus reducing inflammation and preventing the immune system from attacking healthy tissues. For example, in March 2024, the National Health Council, a U.S.-based non-profit organization, reported that autoimmune diseases affect approximately 50 million Americans, with cases increasing by 3-12% annually. Globally, multiple sclerosis cases rose by 30% in 2022 compared to the previous decade. As a result, the increasing prevalence of autoimmune disorders is contributing to the growth of the orencia (abatacept) market.

The rise of personalized medicine is expected to fuel the growth of the orencia (abatacept) market. Personalized medicine involves tailoring treatment and healthcare strategies to an individual's unique genetic makeup, environment, and lifestyle to achieve the most precise and effective outcomes. The growth of personalized medicine is driven by advancements in genomic technologies, a better understanding of molecular biology, the increased availability of precision diagnostic tools, and the demand for targeted therapies that improve patient outcomes while reducing side effects. Orencia (abatacept) plays a role in personalized medicine by targeting specific immune system pathways involved in autoimmune diseases, allowing for customized treatment plans that minimize systemic side effects and optimize therapeutic results based on a patient's unique immune response and disease characteristics. For example, in 2023, the Personalized Medicine Coalition, a U.S.-based organization, reported that in 2022, the FDA approved personalized medicines for 34% of new drugs, and over the prior eight years, at least 25% of new drugs had received approval for personalized treatment. Therefore, the rise of personalized medicine is driving the orencia (abatacept) market.

A key trend in the orencia (abatacept) market is the focus on developing innovative drugs to enhance treatment effectiveness, improve patient outcomes, and address unmet needs in managing autoimmune diseases. Abatacept is a biologic medication used in the treatment of juvenile psoriatic arthritis (JPsA), a rare autoimmune condition affecting children and adolescents, causing joint inflammation and skin lesions. For example, in October 2023, Bristol Myers Squibb, a U.S.-based pharmaceutical company, announced that the FDA approved the Biologics Licensing Application (sBLA) for abatacept (Orencia) to treat juvenile psoriatic arthritis (JPsA) in patients aged 2 to 17 years. This approval was based on controlled studies involving both adults and children, utilizing pharmacokinetic data from studies on adults with rheumatoid arthritis and psoriatic arthritis, as well as safety data from clinical trials involving children aged 2 to 17 years with polyarticular juvenile idiopathic arthritis (JIA).

Key player operating in the orencia (abatacept) market is Bristol-Myers Squibb (BMS).

North America was the largest region in the orencia (abatacept) market in 2024. The regions covered in orencia (abatacept) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the orencia (abatacept) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The orencia market consists of sales of abatacept-based biologic therapies, injectable and intravenous solutions, and immunomodulatory treatments. Values in this market are 'factory gate' values, which represent the value of goods sold by the manufacturers or creators of the goods, whether to other entities (such as wholesalers, distributors, and healthcare providers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Orencia (Abatacept) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on orencia (abatacept) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for orencia (abatacept) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The orencia (abatacept) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Prefilled Syringe; Vial
• 2) By Application: Rheumatoid Arthritis; Juvenile Idiopathic Arthritis; Psoriatic Arthritis
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Companies Mentioned: Bristol-Myers Squibb (BMS)
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.